Cnbx Pharmaceuticals INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
CNBX Pharmaceuticals Inc. has secured a $45,000 non-convertible promissory note from 3i L.P. to fund immediate working capital needs, incurring a 20% premium on all repayments.
OID
CNBX Pharmaceuticals entered into a convertible promissory note agreement for an immediate $55,000 and potential additional funding up to $850,000.
OID
CNBX Pharmaceuticals has replaced its independent auditor, Weinstein International CPA, with Elkana Amitai, CPA, effective March 18, 2024.